The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Top ACR Priorities in 2017 Include Drug Costs, MACRA

Top ACR Priorities in 2017 Include Drug Costs, MACRA

January 4, 2017 • By Kelly Tyrrell

  • Tweet
  • Email
Print-Friendly Version / Save PDF

With a new federal administration and Republican-controlled Congress taking the helm in 2017, the ACR Government Affairs Committee has identified top legislative and regulatory priorities for the year.

You Might Also Like
  • Step Therapy, Biosimilars among ACR’s 2017 State-Level Priorities
  • The ACR’s 2018 Legislative & Regulatory Priorities
  • The ACR Announces Advocacy Priorities for 2016
Also By This Author
  • ACR Honors U.S. Sen. Susan Collins

“The main priority is going to be helping represent the rheumatology community as Medicare is reformed, because the era of MACRA started Jan. 1,” says Angus Worthing, MD, FACR, FACP, chair of the ACR’s Government Affairs Committee (GAC).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Priority No. 1
First and foremost, Dr. Worthing says, is ensuring Medicare does not unfairly penalize rheumatologists for providing biologic drugs.

“If the new system penalizes physicians so severely for appropriate use of medications that [improve] patient quality of life and can be lifesaving, it could be so draconian as to run practices to the ground,” he says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

RISEing Up
Additionally, the ACR will look to maximize the RISE Registry to allow members to effortlessly submit data to the Centers for Medicare and Medicaid Services (CMS).

Working like a “vacuum cleaner,” RISE helps collect data from rheumatologists’ electronic medical records and “find out which quality measures will be most effective for rheumatologists to be reimbursed for our work,” Dr. Worthing says. Participation in the RISE Registry can also position rheumatologists favorably with Medicare payments under MACRA.

Other Key Priorities
Other priorities for the ACR will include:

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  • Supporting reintroduction of the Patients’ Access to Treatment Act, which would eliminate specialty tiers and high co-insurance fees for patients;
  • Use of more transparent biosimilar drug labels, including clinical data, a statement of whether a drug is interchangeable with the original biologic and use of distinct biosimilar names;
  • Protection against substitution of interchangeable biosimilars without proper notification of physicians; and
  • Supporting increased FDA funding and bureaucratic and hiring reforms to ensure adequate resources are available for regulation and advancement of new biosimilars, so that more marketplace competition can drive down excessive costs.

The ACR will also seek to permanently repeal the Medicare physical therapy services cap. Congress has regularly provided exemptions, Dr. Worthing says, but the ACR hopes to help revive bipartisan support for permanent repeal.

With the recent passage of the 21st Century Cures Act, which boosted NIH research funding, Dr. Worthing says the ACR will continue to advocate for $20 million in line-item Defense Department funding for arthritis-related research.

Now off the table will be efforts to fight the Medicare Part B Demonstration Project; it was scrapped by the CMS on Dec. 15, 2016.

“It had been a very large priority,” says Dr. Worthing. “We consider it a victory for the rheumatology community and our patients.”

Pages: 1 2 | Single Page

Filed Under: Practice Management, Professional Topics Tagged With: ACR Government Affairs Committee, federal administration, GAC, MACRA, Medicare, Patients’ Access to Treatment Act, RISE registry

You Might Also Like:
  • Step Therapy, Biosimilars among ACR’s 2017 State-Level Priorities
  • The ACR’s 2018 Legislative & Regulatory Priorities
  • The ACR Announces Advocacy Priorities for 2016
  • ACR Works to Eliminate Part B Drug Costs from MIPS Payment Adjustments

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)